Development of oral vaccine tech for multivalent protection against Shigella

National Institute Of Allergy And Infectious Diseases

Investigators

Abstract

Develop an enabling vaccine technology for protection against the predominant worldwide serotypes of Shigella including S. dysenteriae 1, the cause of epidemic, high mortality disease.